14.03
-0.5(-3.44%)
Currency In USD
| Previous Close | 14.53 |
| Open | 14.53 |
| Day High | 14.62 |
| Day Low | 14.01 |
| 52-Week High | 18.9 |
| 52-Week Low | 10 |
| Volume | 1.67M |
| Average Volume | 1.48M |
| Market Cap | 1.37B |
| PE | -29.23 |
| EPS | -0.48 |
| Moving Average 50 Days | 16.76 |
| Moving Average 200 Days | 13.99 |
| Change | -0.5 |
If you invested $1000 in ARS Pharmaceuticals, Inc. (SPRY) since IPO date, it would be worth $561.2 as of August 18, 2025 at a share price of $14.03. Whereas If you bought $1000 worth of ARS Pharmaceuticals, Inc. (SPRY) shares 3 years ago, it would be worth $2,569.6 as of August 18, 2025 at a share price of $14.03.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results
GlobeNewswire Inc.
Aug 04, 2025 12:00 PM GMT
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to a
EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
GlobeNewswire Inc.
Jul 18, 2025 1:25 PM GMT
EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions ALK-Abelló A/S, which owns the rights to market EURneffy in the U.K., expects availability in
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
May 27, 2025 12:00 PM GMT
SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to